Physician profile
Erika Thomas
NPI 1093375750
$2,104.69
in general payments reported to CMS, 2019-2025
19 companies · $954 in 2025
The $954 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.99 · 2023: $421 · 2024: $703 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $645.10 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $353.85 | 2023-2025 | |
| Pfizer INC. | $294.13 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $189.59 | 2024-2025 | Breztri, Farxiga |
| Exact Sciences Corporation | $115.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $89.61 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Daiichi Sankyo INC. | $88.93 | 2023-2025 | Injectafer |
| Astellas Pharma US INC | $60.56 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.08 | 2024-2025 | Jardiance |
| Optinose US, INC. | $27.74 | 2025 | |
| Masimo Corporation | $26.99 | 2022 | |
| Lundbeck LLC | $25.98 | 2023 | Vyepti |
| Corcept Therapeutics | $24.77 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $22.83 | 2025 | Inspire |
| Corium, LLC | $21.99 | 2024 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $21.62 | 2025 | Skyclarys |
| Otsuka America Pharmaceutical, INC. | $16.63 | 2025 | Rexulti |
| Medtronic, INC. | $14.87 | 2024 | Intellis Adaptivestim |
| Phadia US INC. | $13.19 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.